Illumina handed $27m in prenatal patent win

A California jury has ordered Roche-owned Ariosa Diagnostics to pay US-based gene sequencing company Illumina $27 million in a patent dispute.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Medtech

Predicting the unpredictable during pregnancy

19 April 2022 A pressing need for more non-invasive prenatal tests is leading to increasing IP activity and commercial interest, say Fran Salisbury and Alice Jefferies of Mewburn Ellis.

Americas

Federal Circuit denies Illumina’s writ request in Ariosa dispute

10 March 2017 The US Court of Appeals for the Federal Circuit has said it won’t review a writ filed by Illumina and its subsidiary Verinata Health in a patent dispute with Ariosa Diagnostics.

Europe

Illumina files patent claim against Ariosa and The Doctors Laboratory

8 January 2016 US-based gene sequencing company Illumina has claimed that The Doctors Laboratory’s use of the Harmony prenatal test provided by Ariosa Diagnostics infringes its patent.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Illumina handed $27m in prenatal patent win

More on this story

Editor's picks

Editor's picks

More features